Novel cellular therapies for hepatobiliary malignancies

• Published in: Hepatobiliary & pancreatic diseases international 2022-10, Vol.21 (5), p.450-454
• Main Authors: Xue, Jing-Nan, Wang, Yan-Yu, Wang, Yun-Chao, Zhang, Nan, Zhang, Long-Hao, Lu, Zheng-Hui, Zhao, Li-Jin, Zhao, Hai-Tao
• Format: Article
• Language: English
• Subjects: Cellular therapy; Chimeric antigen receptor T cell therapy; Hepatobiliary malignancy; Receptor-engineered T cell
• ISSN: 1499-3872
• DOI: 10.1016/j.hbpd.2022.08.014

The mortalities of hepatobiliary malignancies are high. With the failure of conventional chemotherapy and unsatisfactory outcome of molecular targeted drugs, immune-based therapy has become a new focus of research in hepatobiliary cancers treatment. We performed a PubMed search with relevant articles published up to May 2022 and the following keywords: cellular immunotherapy, hepatobiliary cancer, antigen receptor T cell therapy, and receptor-engineered T cell. Information of clinical trials was obtained from https://clinicaltrials.gov/. Cell therapies for hepatobiliary malignancies are at early stage of development. The current review showed that cellular therapies are safe and feasible in patients. These findings provide an important platform for future lager scale clinical trials on immunotherapy in patients with hepatobiliary malignancies. With the continuous advances of cellular immunotherapy, the combination of cellular immunotherapy with surgery, chemotherapy and radiotherapy will be new therapeutic strategies for patients with hepatobiliary cancer.